Helicobacter pylori infection is associated with high incidence of gastric diseases. the extensive therapy of H. pylori infection with antibiotics has increased its resistance rates worldwide. ovatodiolide, a pure constituent isolated from Anisomeles indica, has been demonstrated to possess bactericidal activity against H. pylori. In this study, ovatodiolide inhibited the growth of both H. pylori reference strain and clinical multidrug-resistant isolates. Docking analysis revealed that ovatodiolide fits into the hydrophobic pocket of a ribosomal protein, RpsB. Furthermore, ovatodiolide inhibited bacterial growth by reducing levels of RpsB, which plays a crucial role in protein translation. our results demonstrate that ovatodiolide binds to a ribosomal protein and interferes with protein synthesis. this study provides evidence that ovatodiolide has the potential to be developed into a potent therapeutic agent for treating H. pylori infection.
gastrointestinal disease 11 . Despite empirical demonstration of prominent inhibitory effects on H. pylori, mechanisms by which medicinal herbs and plant-derived products harbor anti-inflammatory and/or gastroprotective effects require further investigation.
Anisomeles indica (L) Kuntze (Labiatae) is a traditional Chinese herb called 'yu-chen-tsao' in Chinese. It has been demonstrated to possess anti-inflammatory activity 12 and has been used to treat gastrointestinal diseases 13 . Ovatodiolide, a compound isolated from A. indica, has been reported to exhibit many biological functions, including anti-cancer [14] [15] [16] , anti-bacterial 17, 18 , and anti-HIV activities 19 . Most importantly, our previous studies have demonstrated that ovatodiolide inhibited H. pylori-induced inflammation in gastric epithelial cells 17, 20 . In this study, we further investigated the detailed mechanism of inhibition against H. pylori by ovatodiolide.
Materials and Methods
Chemicals and reagents. Dual Bacterial strains and culture. H. pylori 26695 (ATCC 700392), used as a reference strain was described previously 21 . Multidrug resistant (MDR)-H. pylori strains (v633 and v1354), which were clinical isolates and characterized as resistant to both metronidazole and clarithromycin 22 . All H. pylori strains were routinely cultured on Brucella blood agar plates (Becton Dickinson, Franklin Lakes, NJ) containing 10% sheep blood under 5% CO 2 and 10% O 2 conditions at 37 °C for 48 h. preparation and characterization of ovatodiolide. The isolation of ovatodiolide from A. indica was described previously 20 . The purified ovatodiolide was confirmed by high-performance liquid chromatography transcription/translation assay and luminescence read out. Transcription/translation assay was performed as described previously 23, 24 
Results
ovatodiolide inhibited the growth of H. pylori. Various concentrations of ovatodiolide (0-20 µM) were used against a H. pylori reference strain through a disc agar diffusion assay. At 10 µM and 20 µM, the inhibition zones were measured to be 10 ± 0.5 mm and 19 ± 0 mm, respectively (Table 1) . We then explored whether ovatodiolide possessed bactericidal activity for both reference and clinical MDR-H. pylori strains. As shown in Table 2 , MDR-H. pylori strains (v633 and v1354) showed resistant to erythromycin. However, the minimum bactericidal concentration (MBC) of ovatodiolide for reference and MDR-H. pylori are 200 µM and 100 µM, respectively. These results indicate that ovatodiolide exerted bactericidal activity against both H. pylori reference and MDR strains. ovatodiolide inhibited protein synthesis. Because the structure of ovatodiolide is similar to that of macrolides, we then investigated whether ovatodiolide acts against H. pylori by interrupting the translation process. Protein synthesis activity was determined using an in vitro transcription/translation system. As shown in Fig. 1 , the concentration of ovatodiolide that inhibited 50% of protein synthesis was 2.8 µM. The other two antibiotics, kanamycin and erythromycin, which are protein synthesis inhibitors, inhibited 50% protein synthesis at 0.21 µM and 0.45 µM, respectively. These suggest that ovatodiolide inhibited bacterial growth by interfering with protein synthesis. ovatodiolide functions against ribosomal protein. Multiple ribosomal subunits were used as template RpsB to build the RpsB model ( Fig. 2A) . Template sequence alignments were highly conserved and showed identities of 44.0-51.3% (Fig. 2B,C) . RMSD for C-alpha atom backbones to reference were 1.07-1.22 Å (Fig. 2C ). Model quality was represented via a Ramachandran plot (Fig. 2D ). Since the chemical structure of ovatodiolide resembles that of macrolides (Fig. 3A) , ovatodiolide may inhibit ribosomal proteins in a manner similar to erythromycin. The docking model suggested by the Flexible Docking Program (BIOVIA Discovery Studio) indicated that ovatodiolide occupied the hydrophobic groove of RpsB. The superimpose of docking model with employing multiple ribosomal subunit proteins (Protein Data Bank Codes: 4TOI, 2E5L, 4YHH, 4 × 62, and 1F1G) exhibited that ovatodiolide was occupied the similar binding site of RpsB (Fig. 3A) . Amino acids in RpsB (Lys27, and Tyr47) were observed to directly contact erythromycin ( Fig. 3B,C) . In addition, ovatodiolide interacted with Lys27 and Val194 via hydrogen-bonding with 1.88 Å and 2.54 Å, and with Pro191 and Pro197 through Van der Walls forces (Fig. 3D,E) . Together, the results indicate that ovatodiolide potentially interacts with RpsB.
We then explored whether ovatodiolide inhibited ribosomal proteins and obstructed protein synthesis. After treatment with ovatodiolide, RpsB expression was detected through western blot analysis. As shown in Fig. 4 , the protein expression level of RpsB decreased upon ovatodiolide treatment. These results demonstrate that ovatodiolide fits into a ribosomal protein and may interfere with protein translation.
Discussion
H. pylori colonizes the human stomach and causes several gastrointestinal diseases, including gastritis, peptic ulcer, and gastric adenocarcinoma 27 . Antimicrobial agents are the most effective for eradicating H. pylori infection, particularly through a triple therapy regimen consisting of a proton-pump inhibitor, amoxicillin, and clarithromycin 28 . However, resistance rates have elevated with the use of antimicrobial agents over time 8 . Therefore, it is necessary to discover potent agents for treating H. pylori infection. Accordingly, medicinal herb and plant derived-products with predominant effectiveness and low adverse effects are deserved to be explored.
A. indica extracts possess the ability to ameliorate inflammation 12 . Ovatodiolide, an important constituent of A. indica, has been found to exbibit activity not only against viruses 19 , but against bacteria as well 18 . Our previous study reported that ovatodiolide isolated from A. indica inhibited H. pylori growth 20 . We then demonstrated that A. indica contained a vast amount of ovatodiolide, which exerted the inhibitory effect on H. pylori-induced inflammation 17 . This study further suggested that ovatodiolide may exert bactericidal function by interfering with protein synthesis. Although these findings indicate that ovatodiolide is worth developed into a potential agent against H. pylori growth, long-term in vivo effectiveness and toxicity are warranted to be assessed.
The structure of ovatodiolide resembles that of erythromycin, which may explain its ability to inhibit bacterial protein synthesis. Docking analysis indicated that ovatodiolide and macrolides interact similarly with ribosomal proteins (Fig. 3A) . Multiple sequence alignments showed six highly conserved regions (Fig. S2 ). Docking energy calculations from RpsB-ERY/OVT model results indicated that regions 1 and 6 are potential binding sites ( Supplementary Table S1 ). Furthermore, to address an adequate docking pose, the complex structure of RpsB from Thermus thermophiles (PDB code: 4 × 62) was used to analyze the potential docking pose and potential interaction regions. The composition of complex structure includes 30 s ribosomal subunit and DNA sequence, the potential interaction region was located in region 1 of the docking pose (Suppl Figs S2B and S3 ). Interaction energies for RpsB-ERY and RpsB-OVT models were estimated by CDOCKER as −81.998 and −39.624 Kcal/mol, respectively. Moreover, ovatodiolide exerted activity against ribosomal subunit protein, RpsB (Fig. 4) . These results suggest that the direct binding of ovatodiolide to a ribosomal subunit protein inhibited protein synthesis.
Emergence of MDR-H. pylori is a worldwide health concern. With increasing incidence of antimicrobial resistance, failure rates are sustainably rising 7 . Our previous study indicated that MDR-H. pylori strains (v633 and v1354) presented resistance to macrolides 22 . In this study, we showed that ovatodiolide inhibited both H. pylori reference and MDR strains ( Table 2 ). To address the problem with the rising incidence of antimicrobial resistance, ovatodiolide may be an alternative agent for the therapy of H. pylori infection, particularly in patients infected with MDR strains.
In summary, this study reported that ovatodiolide isolated from A. indica exhibited inhibitory effects against H. pylori growth. We also demonstrated that ovatodiolide not only suppressed the growth of reference H. pylori, but also of MDR strains. In particular, the potential mechanism for the bactericidal activity of ovatodiolide may involve the inhibition of ribosomal translation. Therefore, ovatodiolide may have the potential to be developed into a new therapeutic agent against H. pylori infection.
